Sanofi (EPA:SAN)
France · Delayed Price · Currency is EUR | Market Cap | 91.74B -18.7% |
| Revenue (ttm) | 47.35B +4.8% |
| Net Income | 7.56B +19.9% |
| EPS | 6.20 +23.0% |
| Shares Out | 1.20B |
| PE Ratio | 19.28 |
| Forward PE | 8.86 |
| Dividend | 4.12 (5.39%) |
| Ex-Dividend Date | May 5, 2026 |
| Volume | 2,189,664 |
| Open | 76.80 |
| Previous Close | 76.44 |
| Day's Range | 76.71 - 78.43 |
| 52-Week Range | 71.73 - 91.15 |
| Beta | 0.28 |
| Analysts | Buy |
| Price Target | 97.10 (+24.57%) |
| Earnings Date | Jul 30, 2026 |
About Sanofi
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines that includes hepatitis A, typhoid, yellow fever, and rabies vaccines. It has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for onc... [Read more]
Financial Performance
In 2025, Sanofi's revenue was 46.72 billion, an increase of 5.49% compared to the previous year's 44.29 billion. Earnings were 7.81 billion, an increase of 40.52%.
Financial StatementsAnalyst Summary
According to 24 analysts, the average rating for SAN stock is "Buy." The 12-month stock price target is €97.10, which is an increase of 24.57% from the latest price.
News
Owkin to Build AI Agents as Part of a Multi-Year K Pro Collaboration with Sanofi
NEW YORK & PARIS--(BUSINESS WIRE)--Owkin, the agentic AI company pioneering Biological Artificial Superintelligence to transform drug discovery and development, today announced a multi-year collaborat...
Sanofi SA (SNY) Stock Up 4.7% and Still Undervalued -- GF Score: 71/100
Sanofi SA (SNY) Stock Up 4.7% and Still Undervalued -- GF Score: 71/100
Sanofi Launched 2026 Global Employee Stock Purchase Plan
(RTTNews) - Sanofi (SNY) announced the launch of its 2026 global employee shareholder plan, Action 2026, opening on June 9 to approximately 75,000 employees across 52 countries.
Sanofi: Sanofi launches 2026 global employee stock purchase plan
Sanofi launches 2026 global employee stock purchase plan Paris, June 4, 2026. Sanofi's global employee shareholder plan, Action 2026, opens on June 9, 2026, to around 75,000 employees in 52 countri...
Press Release: Sanofi launches 2026 global employee stock purchase plan
Sanofi launches 2026 global employee stock purchase plan Paris, June 4, 2026. Sanofi's global employee shareholder plan, Action 2026, opens on June 9, 2026, to around 75,000 employees in 52 countries.
Veeva Systems: Veeva Summit Previews Falcon and the Path to Agentic Biopharma
More than 2,000 gathered to see the future of industry AI AOP Health, Boehringer Ingelheim, GSK, Haleon, MSD, Novo Nordisk, Roche, Sanofi, and Sobi among leaders sharing strategies to streamline a...
Sanofi Transcript: Jefferies Global Healthcare Conference 2026
Immunology and vaccines are advancing with multiple phase III trials, global expansion of RSV protection, and a focus on combination vaccines. Strategic adaptation to digital, regulatory, and market changes is underway, with significant BD activity and key data readouts expected in the next year.
Sanofi (SNY) Unveils AI-Driven Sales Support Tool
Sanofi (SNY) Unveils AI-Driven Sales Support Tool
Snowflake says Sanofi selects Snowflake Cortex AI for drug development
Snowflake (SNOW) announced at Snowflake Summit 26 that Sanofi (SNY) has established a new blueprint for AI-powered biopharma with its launch of “Concierge for Field,” a new AI agent built…
Sanofi (SNY) Receives FDA Priority Review for Venglustat Application
Sanofi (SNY) Receives FDA Priority Review for Venglustat Application
Sanofi announces FDA grants priority review to venglustat new drug application
The FDA has granted priority review to Sanofi’s (SNY) new drug application for venglustat, an investigational oral glucosylceramide synthase inhibitor, for the treatment of type 3 Gaucher disease, a r...
Sanofi Gets FDA Priority Review For Venglustat In Type 3 Gaucher Disease
PARIS (dpa-AFX) - Sanofi SA (SNY) on Thursday said the US Food and Drug Administration (FDA) has granted priority review to the new drug application for venglustat for the treatment of type 3 Gauc...
Sanofi: Sanofi's venglustat accepted for priority review in the US to treat type 3 Gaucher disease
Sanofi's venglustat accepted for priority review in the US to treat type 3 Gaucher disease Paris, May 28, 2026. The US Food and Drug Administration (FDA) has granted priority review to the new drug...
Press Release: Sanofi's venglustat accepted for priority review in the US to treat type 3 Gaucher disease
Sanofi's venglustat accepted for priority review in the US to treat type 3 Gaucher disease Paris, May 28, 2026. The US Food and Drug Administration (FDA) has granted priority review to the new drug ap...
Sanofi is building its own AI ecosystem to give the French pharma giant an edge
Sanofi is developing custom tools and reimagining AI workflows, rather than rely on agentic products sold by SaaS vendors.
Sanofi: Information concerning the total number of voting rights and shares - April 2026
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement g...
Sanofi Reports Positive Phase 2 Data For Efdoralprin Alfa In AATD-Related Emphysema
PARIS (dpa-AFX) - Sanofi SA (SNY) reported positive data from the Phase 2 ElevAATe study of efdoralprin alfa in adult patients with alpha-1 antitrypsin deficiency-related emphysema.Alpha-1 Antitry...
Sanofi (SNY) Presents Promising Phase 2 Study Results for Efdoralprin Alfa
Sanofi (SNY) Presents Promising Phase 2 Study Results for Efdoralprin Alfa
1 Dirt Cheap Growth Stock to Buy Right Now
Sanofi is generating some solid growth and it trades at an incredibly low valuation.
Sanofi reports ElevAATe trial of efdoralprin alfa meets primary endpoint
Sanofi (SNY) announced data from the global ElevAATe phase 2 study demonstrated superiority of investigational efdoralprin alfa over standard-of-care therapy in achieving and maintaining normalized fu...
Sanofi says rare lung disease drug outperforms standard care in trial
French drugmaker Sanofi said on Monday a trial showed its rare disease therapy was better than standard care in raising levels of a key protein in patients with a genetic form of lung disease.
Sanofi: ATS: phase 2 data demonstrate the superiority of efdoralprin alfa over a standard-of-care augmentation therapy in achieving higher fAAT levels in AATD
ATS: phase 2 data demonstrate the superiority of efdoralprin alfa over a standard-of-care augmentation therapy in achieving higher fAAT levels in AATD Data from the head-to-head study show efdoralp...
Press Release: ATS: phase 2 data demonstrate the superiority of efdoralprin alfa over a standard-of-care augmentation therapy in achieving higher fAAT levels in AATD
ATS: phase 2 data demonstrate the superiority of efdoralprin alfa over a standard-of-care augmentation therapy in achieving higher fAAT levels in AATD
3 Reasons Not to Buy Into the Hantavirus-Related Biotech Rally
The hantavirus isn't as contagious as the coronavirus, making a global pandemic unlikely. Picking the potential winners in the hantavirus vaccine market would hardly be worth the time and risk.
Sanofi's Strategic Acquisition of AgomAb Therapeutics NV Shares
Sanofi's Strategic Acquisition of AgomAb Therapeutics NV Shares